{"artifact":{"id":"experiment-exp-35dc17bb-762a-401b-beb3-c4899ef58ce2","artifact_type":"experiment","entity_ids":"[\"GPR109A\"]","title":"GPR109A functional modulation with pharmacological agents","quality_score":0.88,"created_by":"experiment_extractor","provenance_chain":"[]","content_hash":"14ba6db8e072ce113bcb9b58a51ee1681c1f24a4669b7032e3123d9c392f21e0","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-10T22:49:25.090779"},"p_value":null,"protocol":"Administration of GPR109A modulators (GSK256073 and mepenzolate bromide) to periodontitis mice, followed by assessment of barrier function and inflammatory markers","effect_size":null,"sample_size":null,"source_pmid":"41816355","extracted_at":"2026-04-10T15:49:24.641402","_schema_version":1,"experiment_type":"animal_model","success_criteria":"Significant improvement in tight junction integrity and reduction in pro-inflammatory cytokines with GPR109A activation","expected_outcomes":"GPR109A activation would reverse barrier disruption and reduce inflammation","statistical_methods":null},"created_at":"2026-04-10T22:49:25-07:00","updated_at":"2026-04-10T22:49:25-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-10T22:49:25-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":"ok","contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"05ea40b1-dabb-428d-8359-16e5ec9f5806","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"experiment_extractor"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"hypothesis-h-3d545f4e","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"target_artifact_id":"experiment-exp-fa0d03e3-261c-4eac-8f67-b02263a7a267","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"target_artifact_id":"experiment-exp-cafc6e59-f753-4298-bee2-7b0dc9047ff2","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"target_artifact_id":"experiment-exp-96ca29f6-fdad-46e2-92e2-2c81c00cffd3","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"target_artifact_id":"wiki-therapeutics-gpr109a-agonists-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GPR109A"}],"incoming_links":[{"source_artifact_id":"experiment-exp-2958fb94-6ae5-4fc8-a45f-26c1e015282e","link_type":"related","strength":0.16666666666666666,"evidence":null},{"source_artifact_id":"experiment-exp-96ca29f6-fdad-46e2-92e2-2c81c00cffd3","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"source_artifact_id":"experiment-exp-fa0d03e3-261c-4eac-8f67-b02263a7a267","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"source_artifact_id":"experiment-exp-cafc6e59-f753-4298-bee2-7b0dc9047ff2","link_type":"related","strength":1.0,"evidence":"Shared entity overlap (Jaccard=1.00)"},{"source_artifact_id":"hypothesis-h-3d545f4e","link_type":"related","strength":0.6,"evidence":"Both artifacts share KG entity: 'gpr109a'"},{"source_artifact_id":"wiki-therapeutics-gpr109a-agonists-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GPR109A"},{"source_artifact_id":"open_question-17153a0a-1a74-43e5-89ca-f91ad360540e","link_type":"partial_answer_for","strength":0.63,"evidence":"{\"confidence\": 0.63, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"}],"current_artifact_id":"experiment-exp-35dc17bb-762a-401b-beb3-c4899ef58ce2","is_canonical":true,"supersede_chain":["experiment-exp-35dc17bb-762a-401b-beb3-c4899ef58ce2"]}